CXCR5 and rheumatoid arthritis: Rather, our data suggest that RA subjects who have a heightened CXCR5+Th17 immune response may also be less likely to achieve complete remission by TNFi therapies compared to RA that is dominated by other immune pathways (such as synovial fibroblast-macrophage circuits).